Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.

Article  PubMed  Google Scholar 

Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiat. 2019;76:1052–62.

Article  Google Scholar 

Albitar O, Harun SN, Zainal H, Ibrahim B, Sheikh Ghadzi SM. Population pharmacokinetics of clozapine: a systematic review. Biomed Res Int. 2020;2020:1–10.

Article  Google Scholar 

Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46:453–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albitar O, Ghadzi SMS, Harun SN, Ahmad SNA, Kjellsson MC. Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine. J Pharmacokinet Pharmacodyn. 2023;50:21–31.

Article  CAS  PubMed  Google Scholar 

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.

Article  PubMed  Google Scholar 

Yu H, Steeghs N, Kloth JSL, de Wit D, van Hasselt JGC, van Erp NP, et al. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol. 2015;79:809–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albitar O, Murugaiyah V, Ibrahim B, Ahamed N, Sheikh Ghadzi SM. Clozapine and norclozapine monitoring in plasma following surfactant assisted dispersive liquid–liquid microextraction. Sep Sci Plus. 2022;5:55–64.

Article  CAS  Google Scholar 

Beal SL, Shiener LB, Boeckman AJ. NONMEM users guides (1989–2008). Ellicott City: Icon Development Solutions; 2008.

Google Scholar 

Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol. 1988;34:445–9.

Article  CAS  PubMed  Google Scholar 

Jann MW, Griley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin. Pharmacokinet. Adis International Ltd; 1993. p. 161–76.

Fitton A, Heel RC. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 1990;40:722–47.

Article  CAS  PubMed  Google Scholar 

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther. 2010;88:643–51.

Article  CAS  PubMed  Google Scholar 

Carlisle KM, Halliwell M, Read AE, Wells PNT. Estimation of total hepatic blood flow by duplex ultrasound. Gut. 1992;33:92–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guitton C, Kinowski J-M, Gomeni R, Bressolle F. A kinetic model for simultaneous fit of clozapine and norclozapine concentrations in chronic schizophrenic patients during long-term treatment. Clin Drug Investig. 1998;16:35–43.

Article  CAS  PubMed  Google Scholar 

Chan Kwong AH-XP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47:431–46.

Article  PubMed  PubMed Central  Google Scholar 

Keizer R, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:1–9.

Article  Google Scholar 

Jonsson EN, Karlsson MO. Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1998;58:51–64.

Article  Google Scholar 

Hooker AC, Karlsson MO, Wilkins JJ, Jonsson EN. xpose4: Tools for nonlinear mixed-effect model building and diagnostics. R package version 4.6.1. (2014). http://xpose.sourceforge.net. Accessed 17 Feb 2020.

Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JHM, Huitema ADR. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J. 2012;14:601–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.

Article  PubMed  PubMed Central  Google Scholar 

Dosne AG, Bergstrand M, Harling K, Karlsson MO. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn. 2016;43:583–96.

Article  PubMed  PubMed Central  Google Scholar 

Shang D-W, Li L-J, Wang X-P, Wen Y-G, Ren Y-P, Guo W, et al. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia. Ther Drug Monit. 2014;36:378–86.

Article  CAS  PubMed  Google Scholar 

Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res. 1987;04:402–5.

Article  CAS  Google Scholar 

Jerling M, Merlé Y, Mentré F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997;44:447–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dailly E, Urien S, Chanut E, Claudel B, Guerra N, Fernandez C, et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26:699–703.

Article  CAS  Google Scholar 

Doude van Troostwijk LJA, Koopmans RP, Vermeulen HD, Guchelaar H-J. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci. 2003;20:451–7.

Article  CAS  PubMed  Google Scholar 

Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31:360–6.

Article  CAS  PubMed  Google Scholar 

Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20:53–60.

Article  PubMed  Google Scholar 

Li L, Shang D, Li W, Guo W, Wang X, Ren Y, et al. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. Acta Pharmacol Sin. 2012;33:1409–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li A-N, Dong F, He J-L, Shang D-W, Guo W, Li W-B, et al. The elimination rate after clozapine overdose in Chinese schizophrenia patients: a population pharmacokinetics model study. Pharmacopsychiatry. 2015;48:150–5.

Article  CAS  PubMed  Google Scholar 

Olmos I, Ibarra M, Vázquez M, Maldonado C, Fagiolino P, Giachetto G. Population pharmacokinetics of clozapine and norclozapine and switchability assessment between brands in uruguayan patients with schizophrenia. Biomed Res Int. 2019;2019:1–10.

Article  Google Scholar 

Reeves S, Bertrand J, Obee SJ, Hunter S, Howard R, Flanagan RJ. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol. 2024;90:135–45.

Qiu X-W, Fu P-X, Wang C-Y, Liu M, Zhou T-Y, Lu W. Population pharmacokinetics research of clozapine in Chinese schizophrenic patients. Yao Xue Xue Bao. 2009;44:785–92.

CAS  PubMed  Google Scholar 

Özdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. J Clin Psychopharmacol. 2001;21:398–407.

Article  PubMed  Google Scholar 

Twesigomwe D, Drögemöller BI, Wright GEB, Adebamowo C, Agongo G, Boua PR, et al. Characterization of CYP2D6 pharmacogenetic variation in sub-Saharan African populations. Clin Pharmacol Ther. 2023;113:643–59.

Article  CAS  PubMed  Google Scholar 

Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, Popejoy AB, et al. Standardized biogeographic grouping system for annotating populations in pharmacogenetic research. Clin Pharmacol Ther. 2019;105:1256.

Article  PubMed  Google Scholar 

Ding J, Liu J, Zhang Y, Xing H, Zhang Y, Li L, et al. A retrospective study of clozapine and norclozapine concentration in patients with schizophrenia: data from the Therapeutic Drug Monitoring Service, 2019–2022. Asian J Psychiatr. 2024;91: 103865.

Article  PubMed  Google Scholar 

Flanagan RJ, Gee S, Belsey S, Couchman L, Lally J. Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations. BJPsych Adv. 2023;29:92–102.

Article  Google Scholar 

Pardiñas AF, Kappel DB, Roberts M, Tipple F, Shitomi-Jones LM, King A, et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. The Lancet Psychiatry. 2023;10:209–19.

Article  PubMed  PubMed Central